1. KU Leuven Institute for Healthcare Policy, Department of Public Health and Primary Care, University of Leuven - KU Leuven, Leuven, Belgium;
2. KU Leuven Institute for Healthcare Policy, Department of Public Health and Primary Care, University of Leuven- KU Leuven, Leuven, Belgium;
3. Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, UK;
4. Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy, and Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Turin, Italy;
5. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland;
6. Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK;
7. Outpatient Department for ALS and other Motor Neuron Diseases, Charité - Universitätsmedizin Berlin, Berlin, Germany;
8. Department of Neuroscience and Rehabilitation, Fondazione Salvatore Maugeri IRCCS, Milan, Italy;
9. Department of Neurosciences, VIB-Vesalius Research Center, Experimental Neurology-Laboratory of Neurobiology, University of Leuven - KU Leuven, Leuven, Belgium and Department of Neurology, University Hospitals Leuven, Leuven, Belgium;
10. Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands;
11. KU Leuven Institute for Healthcare Policy, Department of Public Health and Primary Care, University of Leuven – KU Leuven, Leuven, Belgium and Department of Quality Management, University Hospitals Leuven, Leuven, Belgium;
12. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany;
13. Walter Sermeus, KU Leuven Institute for Healthcare Policy, Department of Public Health and Primary Care, University of Leuven - KU Leuven, Leuven, Belgium